High cholesterol: At-home hand test to check risk of retinal artery occlusion – experts
HIGH cholesterol left untreated is known to increase a person's risk of retinal artery occlusion which could lead to permanent vision loss. Knowing the signs is crucial and following an at-home hand test could determine your risk. What to spot? (Source: Daily Express - Health)
Source: Daily Express - Health - February 6, 2022 Category: Consumer Health News Source Type: news

Regenerative Patch Technologies Presents Clinical Data Demonstrating Long-Term Survival and Function of an Allogenic Bioengineered Cellular Implant in Patients with Advanced Dry Aged-Related Macular Degeneration
Clinical and Histological Results Signal Prolonged Effectiveness in the Treatment of Advanced Retinal Degenerative Diseases MENLO PARK, Calif., Feb. 4, 2022 -- (Healthcare Sales & Marketing Network) -- Regenerative Patch Technologies LLC (RPT) announce... Regenerative Medicine, Ophthalmology Regenerative Patch Technologies, CPCB-RPE1 implant, cell-based implant (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 4, 2022 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021
Basel, 3 February 2022Group sales increase 9%1 at constant exchange rates (CER); 8% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for newly launched medicines more than offsets impact of biosimilarsDiagnostics Divisionsales grow 29%; strong momentum in base business and continued high demand for COVID-19 testsMajor approvals for medicinessince the last quarter: United States: Susvimo and Vabysmo (age-related blindness)Europe: Gavreto (specific type of advanced lung cancer); Actemra/RoActemra (severe COVID-19); Ronapreve (non-hospitalised COVID-19 patients and prophylaxis)Major appro...
Source: Roche Investor Update - February 3, 2022 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021
Basel, 3 February 2022Group sales increase 9%1 at constant exchange rates (CER); 8% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for newly launched medicines more than offsets impact of biosimilarsDiagnostics Divisionsales grow 29%; strong momentum in base business and continued high demand for COVID-19 testsMajor approvals for medicinessince the last quarter:United States: Susvimo and Vabysmo (age-related blindness)Europe: Gavreto (specific type of advanced lung cancer); Actemra/RoActemra (severe COVID-19); Ronapreve (non-hospitalised COVID-19 patients and prophylaxis)Major approvals f...
Source: Roche Media News - February 3, 2022 Category: Pharmaceuticals Source Type: news

Trials Show Promise for Intravitreal Faricimab in Retinal Disease
WEDNESDAY, Feb. 2, 2022 -- Faricimab is noninferior to aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema, according to two studies published online Jan. 24 in The Lancet. Jeffrey S.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 2, 2022 Category: Pharmaceuticals Source Type: news

A baby carrier fall leading to intracranial bleeding and multilayered retinal hemorrhages - Raj A, Christian CW, Reid JE, Binenbaum G.
[The publisher has not provided an abstract for this article.] Language: en... (Source: SafetyLit)
Source: SafetyLit - January 31, 2022 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news

FDA approves Roche ’s Vabysmo, the first bispecific antibody for the eye, to treat two leading causes of vision loss
Basel, 31  January 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Vabysmo™ (faricimab-svoa) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). Neovascular AMD and DM E are two leading causes of vision loss worldwide.1 Vabysmo targets and inhibits two disease pathways linked to a number of vision-threatening retinal conditions by neutralising angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A).2 Vabysmo is the first and only FDA-approved injectable eye medicine...
Source: Roche Media News - January 31, 2022 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Vabysmo, the first bispecific antibody for the eye, to treat two leading causes of vision loss
Vabysmo (faricimab-svoa) targetsand inhibitstwodiseasepathways that drive neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME)Vabysmo is the only injectable eye medicine approved simultaneously in the US for nAMD and DME, with flexible dosing regimens based on patient needBasel, 31  January 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Vabysmo™ (faricimab-svoa) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). Neovascular AMD and DM E...
Source: Roche Investor Update - January 31, 2022 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Vabysmo, the first bispecific antibody for the eye, to treat two leading causes of vision loss
Vabysmo (faricimab-svoa) targetsand inhibitstwodiseasepathways that drive neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME)Vabysmo is the only injectable eye medicine approved simultaneously in the US for nAMD and DME, with flexible dosing regimens based on patient needBasel, 31  January 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Vabysmo™ (faricimab-svoa) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). Neovascular AMD and DM E...
Source: Roche Media News - January 31, 2022 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Vabysmo, the first bispecific antibody for the eye, to treat two leading causes of vision loss
Basel, 31  January 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Vabysmo™ (faricimab-svoa) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). Neovascular AMD and DM E are two leading causes of vision loss worldwide.1 Vabysmo targets and inhibits two disease pathways linked to a number of vision-threatening retinal conditions by neutralising angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A).2 Vabysmo is the first and only FDA-approved injectable eye medicine...
Source: Roche Investor Update - January 31, 2022 Category: Pharmaceuticals Source Type: news

Retinal Age Gap Predicts Mortality Risk in Older Adults Retinal Age Gap Predicts Mortality Risk in Older Adults
The gap between the biological age of the retina and the chronological age of a patient helps predict mortality risk with good accuracy in seemingly healthy older adults.Medscape Medical News (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - January 27, 2022 Category: Opthalmology Tags: Ophthalmology News Source Type: news

' Retinal Age Gap' Linked to Arterial Stiffness and CVD Risk'Retinal Age Gap' Linked to Arterial Stiffness and CVD Risk
Retinal age gap, defined as age predicted from the fundus image minus chronologic age, is associated with the arterial stiffness index and may be a novel biomarker for subclinical CVD.First Look (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - January 26, 2022 Category: Opthalmology Tags: Cardiology News Source Type: news

NIH study classifies vision loss and retinal changes in Stargardt disease
Research sheds light on severity for gene variants; establishes outcome measures for therapeutic trials. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - January 25, 2022 Category: American Health Source Type: news

Nanoscope Therapeutics Announces FDA Clearance of IND for MCO-010 Gene Therapy in Stargardt Macular Degeneration Patients
BEDFORD, Texas, Jan. 25, 2022 -- (Healthcare Sales & Marketing Network) -- Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced it received IND clearance from the ... Regenerative Medicine, Ophthalmology, FDA Nanoscope Therapeutics, Stargardt, optogenetic, gene therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 25, 2022 Category: Pharmaceuticals Source Type: news

The Lancet publishes studies showing Roche ’s faricimab improved and maintained vision in two leading causes of vision loss, extending time between treatments up to four months
Basel, 24 January 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that The Lancet has published two papers highlighting one-year results from four pivotal phase III studies of faricimab, an investigational bispecific antibody, in neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). [1,2] All four studies – which enrolled more than 3,000 people in total – met their primary endpoints, showing that people treated with faricimab up to every four months achieved non-inferior vision gains compare d to aflibercept given every two months. Notably, about half of eligible f...
Source: Roche Media News - January 24, 2022 Category: Pharmaceuticals Source Type: news